Clinical Trial

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2021-02-12; most recent amendment 2026-03-24.
Status change: Recruiting → Active, Not Recruiting 2025-09-04
Status change: Not Yet Recruiting → Recruiting 2021-06-25
Trial Details
NCT Number NCT04756726
Lead Sponsor C4 Therapeutics, Inc.
Conditions Multiple Myeloma, Lymphoma, Non-Hodgkin's
Enrollment 224 participants
Start Date 2021-04-27
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-25